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Summary:  
Adding community-based scheduled malaria screening and treatment to existing intermittent 
preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) strategies did not reduce malaria in 
pregnancy. Increasing the number of IPTp-SP doses given during pregnancy continues to be a priority. 
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Background: We investigated whether adding community scheduled malaria screening and treatment 
(CSST) with artemether-lumefantrine  by community health workers (CHW) to standard Intermittent 
preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) would improve maternal and infant 
health. 
Methods: In this two-arm cluster, randomised, controlled trial, village clusters in Burkina Faso, The 
Gambia, and Benin were randomised to receive CSST plus IPTp-SP or IPTp-SP alone. CHWs in the 
intervention arm performed monthly CSST during pregnancy. At each contact filter paper and blood 
slides were collected and at time of delivery, a placental biopsy was collected. Primary and secondary 
endpoints were the prevalence of placental malaria, maternal anaemia, maternal peripheral infection, 
low birth weight, ANC attendance and coverage of IPTp-SP. 
Results: Malaria infection was detected by RDT at least once for 3.8% women in The Gambia, 16.9% in 
Benin, and 31.6% in Burkina Faso. There was no difference between intervention and control arms in 
terms of placenta malaria after adjusting for birth season, parity, and IPTp-SP doses (Adj OR: 1.06; 
95%CI: 0.78-1.44, p=0.72). No difference between the intervention and control arm was found for 
peripheral maternal infection, anaemia, and adverse pregnancy outcomes. ANC attendance was 
significantly higher in the intervention arm in Burkina Faso but not in The Gambia and Benin. Increasing 
number of IPTp-SP doses was associated with a significantly lower risk of placenta malaria, anaemia at 
delivery and low birth weight.  
Conclusions: Adding CSST to existing IPTp-SP strategies did not reduce MiP. Increasing the number of 
IPTp-SP doses given during pregnancy is a priority. 
 
Introduction  
Malaria causes significant adverse pregnancy outcomes, such as maternal anaemia, preterm 
delivery,low birth weight, [1] and even maternal and infant death. [2, 3]    The World Health 
Organization (WHO) recommends several interventions to control malaria during pregnancy, namely 1) 
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effective case management, 2) Long-lasting insecticidal nets (LLIN), and 3) Intermittent preventive 
treatment with sulfadoxine-pyrimethamine (IPTp-SP) from the second trimester onwards. [4]  
 
The protective efficacy of IPTp-SP against malaria infection depends on the number of IPTp-SP doses 
administered, which in turn depends on ANC attendance. In many sub-Saharan African (sSA) countries 
both ANC and IPTp-SP coverage remains low. [5] [6]. In addition, SP resistance is increasing and may 
impact on current IPTp-SP policy. [7]. In West Africa, where SP resistance is low, [8] an alternative 
strategy of intermittent screening and treatment (ISTp) was non-inferior to IPTp-SP in preventing low 
birth weight, anaemia, and placental malaria. In eastern-southern Africa, it was associated with a higher 
malaria risk, possibly because of the low sensitivity of currently available rapid diagnostic tests in 
detecting low-density infections. [9, 10] WHO does not recommend ISTp alone.  However, there is the 
need to both improve ANC coverage and protect pregnant women against malaria between ANC visits. 
ISTp at village level could be beneficial if given in addition to IPTp-SP at ANC. Community health workers 
(CHWs) have been trained in many sSA countries to perform community case management of malaria 
(CCMm), and could be trained to encourage pregnant women to attend ANC, and to systematically 
screen and treat them between ANC visits. [11]   
A cluster randomised controlled trial was designed to  establish whether adding community scheduled 
malaria screening and treatment (CSST) by CHWs to standard IPTp-SP would further reduce placental 
malaria compared to IPTp-SP alone. [12]  
 
Methods 
Study sites and participants 
A description of the study methods has been published elsewhere.[12] The study was implemented in 
three West African countries: Burkina Faso (Nanoro health district), The Gambia (Upper River Region), 
and Benin (Glo-Djigbe, Zinvie and Ze districts). In Burkina Faso and The Gambia malaria is highly 
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seasonal (July-December) while in Benin it is perennial with peaks during the rainy seasons (April-July 
and October-November). In all villages, community consent was obtained after sensitisation meetings. 
All resident pregnant women were invited to participate after individual signed informed consent.  
 
Randomisation and blinding 
Thirty villages (clusters) (village population: 1,000-2,000) with CHWs in each country were randomly 
selected from all eligible clusters. Distance from the centre of each village to the nearest health facility 
was calculated and used to group the clusters into three distance categories. Randomisation was 
performed using a computer-based randomisation (StataCorpLP,, http://www.stata.com) and was 
stratified by the three distance categories.   
 
Procedures (Fig 1) 
At the antenatal clinic (ANC) 
Recruitment was done at first ANC. All women had a physical examination, a blood slide and a blood 
sample on filter paper. Information on health and socio-economic factors was also collected. Pregnant 
women in the second or third trimester women were given their first IPTp-SP and their second dose 
booked in. A health assessment was carried out at each ANC visit. Suspected malaria cases had a rapid 
diagnostic test (RDT, SD Bioline, specificity 99.5%) and women testing positive were treated with 
artemether-lumefantrine (AL).  
 
Community health worker home visits in the intervention arm 
CHWs in the intervention arm were trained in malaria case management, and malaria in pregnancy, 
including the benefit of early ANC attendance and IPTp-SP. CHWs were asked to continuously identify all 
pregnant women and encourage them to attend the ANC as early as possible. Thereafter, at monthly 
intervals up to the last week of gestation, CHWs performed a RDT at home visits and collected a blood 
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slide , regardless of malaria symptoms. They gave AL to all positive women. Severely ill women were 
referred to the health centre for further care. The CHWs in the control villages did not take part in any 
of the study training.  
 
 
At time of delivery for all communities 
A blood sample for haemoglobin measurement and on slide and filter paper for later parasitological 
diagnosis was collected just before delivery and a placenta biopsy was collected at delivery. Current 
health status and birth outcomes were collected. All new-borns were physically examined and weighed 
on digital scales immediately after delivery. Gestational age was estimated using the Ballard score.[13]   
 
Laboratory methods 
Giemsa-stained thick blood films were read by two experienced microscopists, with discrepancies 
resolved by a third one. [12] Maternal haemoglobin was measured using Hb301 Hemocue® ( 
Radiometer Group, Sweden). Blood spots on filter paper were analysed by P. falciparum diagnostic 
PCR.[14, 15]  
 
Details of biopsy methods can be found elsewhere. [12]  Placental biopsies slides were read by trained 
microscopists and classified as infected: acute (parasites and malaria pigment absent), chronic 
(parasites and malaria pigment) or past (only malaria pigment), or not infected (no parasites or 
pigment). [16] 
 
Outcomes  
The primary outcome was placental malaria (any category). However, in Benin, rumours on placental 
biopsies had a negative impact on recruitment and, after discussions with the DSMB and the local ethics 
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committee, it was decided to collect only peripheral blood. Secondary endpoints were maternal 
anaemia (haemoglobin <11 g/dL) at delivery, maternal P. falciparum peripheral infection at delivery 
(PCR) and during pregnancy (microscopy), low birth weight (<2,500grams), IPTp-SP coverage, the 
number of ANC visits and the number of IPTp-SP doses. Serious adverse events (SAEs) were defined as 
any untoward medical occurrence that resulted in death, hospitalisation, persistent or significant 
disability/incapacity, or a congenital anomaly/birth defect or life-threatening. All SAEs were reported to 
the DSMB.  
 
Statistical analysis  
It was assumed that the intervention would decrease placental malaria from 15% to 10.5%, with a  co-
efficient of variation of 0.15.  Within each country, 15 clusters, each with 60 pregnant women  per arm, 
would be able to detect a significant difference with 80% power and at the 5% significance level. Thus, 
90 clusters with a total of 5,400 women was required. All data were double entered using OpenClinica© 
databases.  
The primary endpoint (prevalence of placental malaria) was examined with logistic regression. Random 
effects for trial cluster were used to account for intra-cluster correlation. An analysis of the primary 
endpoint adjusted for season, gravidity, and number of SP and AL doses was carried out. All other binary 
endpoints were examined with random effects logistic regression. Count data were analysed with mixed 
effects Poisson regression and continuous data were analysed with mixed effects linear regression.   
 
Ethical approval  
The study was done in accordance with the principles set forth in the Declaration of Helsinki and the 
International Conference on Harmonisation Tripartite Guidelines for Good Clinical Practice. Independent 
trial monitors visited each site throughout the study to ensure compliance with Good Clinical Practice 
standards. The trial was approved by the Gambia Government/MRC Joint Ethics Committee (ref 
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SCC1336);  the Comité d’Ethique Institutionnel du Centre Muraz in Burkina Faso (ref A20-2013/CE-CM); 
and  the Comité National d’Ethique pour la Recherche en Santé in Benin (No_0126/MS /DC/SGM /DFR 
/CNERS/SA). A data safety monitoring board (DSMB) to review the trial procedures and results was set 
up.  The trial is registered at Current Controlled Trials: ISRCTN37259296 (5 July 2013), and 
clinicaltrials.gov: NCT01941264 (10 September 2013). 
 
Results 
Recruitment, baseline characteristics and follow up 
Between November 2013 and November 2015, 4,731 pregnant women were recruited (Figure 2, Fig 
S1a-c), with Benin having recruited only half of the expected sample size.  Loss to follow up was low in 
the Gambia (113/1960=5·8%) and in Burkina Faso (62/1800=3·4%) but high in Benin (290/971=29·9%). 
Overall, 4,266 (90·2%) women completed the follow up and delivered in study (Figure 2). 
In each country, baseline characteristics between intervention and control groups were similar. Use of 
insecticide-treated bed nets was >70%, and malaria prevalence was 5.3%  in The Gambia (101/1888), 
27.9% inBurkina Faso (501/1797), and 30.0% in Benin (288/959). About 20% were primigravidae (Table 
1).   
Most women in the intervention arm had at least one CSST by CHWs with coverage higher in Burkina 
Faso (860/900=96%) and The Gambia (978/1008=97%) compared to Benin (474/542=87·5%).  Overall, 
CHWs performed 7,236 CSST, with an average of 3-4 home visits per woman (Table S1). The mean 
number of slides per woman was significantly higher in the intervention than in the control group 
(Burkina Faso: Means Ratio (MR)=1·62, 95%CI: 1·50, 1·74; The Gambia: MR=2·08, 95%CI: 1·98, 2·19; 
Benin: MR=2·04, 95%CI: 1·87, 2·23)(p<0·001). Malaria infection was detected by RDT at least once for 75 
(3·8%) women in The Gambia, 164 (16·9%) in Benin and 568 (31·6%) in Burkina Faso, and most received 
AL (Table 2 and S1). The number of pregnant women diagnosed with a malaria infection was 
significantly higher in the intervention than in the control arm (p<0·01 for all study sites). A high 
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proportion of infected women received AL, with no difference between study arms in Burkina Faso and 
The Gambia.  In Benin, the proportion of treated women was higher in the intervention 
(172/191=90·0%) than in the control arm (14/33=42·4%) (OR: 1·71, 95% CI: 0·99-2·94, p=0·055).  
 
The effect of the intervention on placenta malaria   
Data from placental biopsies was available for 88% (3171/3585) of deliveries in Burkina Faso and The 
Gambia. There was no difference between intervention and control arms in terms of placenta malaria or 
for different categories of infection (Table 3) and did not change after adjusting for season of birth, 
parity and number of IPTp-SP administered (Adj OR: 1·06; 95%CI: 0·78-1·44, p=0·72) (Table 4). Similar 
results were observed at country level (Tables S2 and S3).  
 
The effect of the intervention on other secondary outcomes at delivery 
There was no difference between arms in peripheral maternal infection (OR: 0·97; 95%CI 0·78-
1·21)(p=0·7), even after adjusting for several factors (Adj OR: 0·92; 95%CI 0·74-1·15)(p=0·4) (Table 5; 
country-specific data in Table S3). Anaemia (OR 1·09; 95%CI: 0·92-1·28) (p=0·3) (Table 6 and S4), mean 
Hb (mean difference: 0·01; 95%CI: -0·29, 0·31)(P=0·9), low birthweight (OR: 1·06; 95%CI: 0·82-
1·38)(p=0·6) (Table 7 and S5), and adverse pregnancy outcomes (Table 8, and Table S6) did not different 
between study arms. Nevertheless, in Burkina Faso,  the odds of miscarriage tended to be higher in the 
intervention arm (OR: 4·54, 95% CI: 0·98-21·05, p=0·054) (Table S6a). Among these women, 3 had a 
malaria infection at least once during pregnancy (2 in the intervention arm and 1 in the control arm), 
and 2 received 1 course of AL (1 in each arm), with no drug-related serious adverse event recorded. 
There was no evidence that taking AL during pregnancy was associated with any adverse pregnancy 
outcome (at least 1 course of AL: OR: 0·82, 95% CI: 0·35-1·93, p=0·656).  
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There were 9 maternal deaths (6 in the control arm and 3 in the intervention arm) and 45 perinatal 
deaths that occurred at time of delivery (21 in control vs 24 in intervention arm).  Causes attributed to 
the SAEs, including maternal and perinatal death, are reported in Table S8. 
 
ANC attendance and IPTp-SP uptake during pregnancy  
Antenatal clinic attendance (scheduled visits) was significantly higher in the intervention arm in Burkina 
Faso but not in The Gambia and Benin (Table 9 and S7). However, IPTp-SP coverage, i.e. mean number 
of doses and percentage of women who received at least 2 or 4 doses, was not significantly different 
between intervention and control arms.  
The effect of IPTp-SP on pregnancy outcomes 
Increasing number of IPTp-SP doses was associated with a significantly lower risk of placenta malaria 
(Table 4), mainly because of Burkina Faso where 49·2% (886/1800) of women had received  ≥3 IPTp-SP 
doses (Table S3a), while in The Gambia this figure was only 3·7% (73/1960) (Table S3b). Placenta malaria 
occurred significantly less during the rainy than the dry season (Adj OR 0·59; 95%CI: 0·49-
0·71)(p<0·001), and was more frequent with increasing number of AL treatments (Table 4).  
Increasing number of IPTp-SP doses tended to decrease the risk of anaemia at delivery (p=0·06), while 
increasing number of AL treatments had the opposite effect (p=0·02)(Table 6 and S4). Similarly, the risk 
of low birth weight decreased significantly with the increasing number of IPTp-SP doses (p<0·001)(Table 
7 and S5).  
 
 
Discussion  
Adding CSST by CHW to the standard IPTp-SP at ANC did not reduce the risk of placenta malaria or 
peripheral malaria infection at delivery. The intervention also aimed at increasing the ANC attendance, 
particularly in early pregnancy, and at identifying and treating infections between scheduled ANC visits. 
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Scheduled ANC attendance did improve in Burkina Faso suggesting that the intervention had the 
expected effect. During the trial, the 2013 WHO recommendations of at least 4 ANC visits and of 
administering IPTp-SP at each of them [17] had been implemented in Burkina Faso, with some women 
havingas many as 6-7 scheduled ANC visits.. In The Gambia and Benin, the national policy was still two 
scheduled visits, and thus we did not expect an increase in the number of ANC visits but rather an 
increase in coverage of two ANC visits. ANC attendance remained extremely low in Benin, only slightly 
more than half of the women had two visits, and this may reflect the general poor attendance in 
southern Benin. In The Gambia, ANC attendance was already high, with 80% of the women attending at 
least 2 scheduled visits, and this may explain why the intervention did not have the expected effect.  
In all countries, the higher number of malaria infections diagnosed in the intervention group and the 
high proportion of malaria positive women treated with AL indicate that CHWs implemented the 
intervention according to the instructions received. In Burkina Faso, RDT’s sensitivity and specificity 
performed by CHWs and compared to microscopy was 81·5% (95% confidence interval [CI] 67·9–90·2) 
and 92·1% (95% CI89·9–93·9), respectively,[14] further confirming CHWs can both correctly use RDTs 
and adhere to test results and treatment guidelines.[18] Previous studies have shown CHWs are able to 
diagnose and treat malaria in children [19-22] and are able to distribute IPTp to pregnant women.[23]  
Though the intervention did not have a direct effect on the prevalence of past placenta malaria, 
probably because of infections before the first ANC visit, one would have expected a reduced risk of 
active or chronic placenta infections. This was not the case, and this may have been due to low 
adherence to AL treatment. However, CHWs who visited treated women 3 days after CSST; 96% of 
women reported having completed the full course; in contrast, a qualitative study carried out in the 
same study area reported that low adherence to anti-malarial treatment by pregnant women despite 
good knowledge about malaria in pregnancy.[24]  
Increasing doses of IPTp-SP significantly decreased the risk of placenta malaria. This effect was mainly 
seen in Burkina Faso, where women received up to 6 IPTp-SP doses. In The Gambia and Benin, the large 
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majority of women had taken only 2 IPTp-SP doses and in both countries malaria prevalence was lower 
than in Burkina Faso. In these 2 countries, CSST should have had some effect as the time between IPTp-
SP doses was longer than in Burkina Faso so that diagnosing and treating infections during this period 
should have been beneficial. Malaria screening by the CHWs was done with an RDT whose detection 
threshold is at most 200 parasites per μL.[25] However, the large majority of infections during 
pregnancy are asymptomatic, with low parasite densities, often not detected by microscopy or RDT.[26] 
Therefore, measurements of the efficacy of intermittent screening and treatment may be limited by the 
sensitivity of current RDTs [10]. The decreased risk of low birth weight with increasing IPTp-SP doses, 
and the borderline decrease of maternal anaemia at delivery confirms the meta-analysis of 7 trials 
carried out in sSA that reported a lower risk of low birth weight, maternal anaemia and placenta malaria 
in women having received ≥3 IPTp-SP doses.[27]. These results were used to support the WHOs’ 
recommendation of administering IPTp-SP at each ANC, provided the doses are at least a month apart. 
The current trial data support this recommendation.  
Pregnant women in the intervention arm had a higher risk of being malaria positive, not because they 
had a higher risk of being infected, rather they were tested more frequently. Considering most 
infections diagnosed in the intervention arm were treated with AL and that the risk of placenta malaria 
increased with the number of AL treatments administered, these infections probably represented a 
small proportion of all infections acquired during pregnancy and it was the undiagnosed infections that 
had a significant effect on the occurrence of placenta malaria. Receiving multiple AL treatments is 
probably a marker of a higher malaria risk. There is some controversy on the importance of low-density 
malaria infections during pregnancy, associated with  anaemia, lower mean Hb, low birth weight, and 
premature births in some studies [28] but not in others.[26] Our results indicate that such infections are 
important and that, until better diagnostic tests than standard RDTs become available, systematic 
treatment as many times as possible of all pregnant women until delivery is the best approach.  
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A major strength of this study was the selection of countries based on their varying malaria endemicity: 
low (The Gambia) versus high (Burkina Faso and Benin), and with varying degrees of SP resistance (high 
in Benin and moderate in The Gambia and Burkina Faso) which enables to generalise study findings to 
West Africa and possibly other sSA countries.  The study was powered for individual countries for the 
overall primary outcome, thus we were able to at least fully investigate the effect of the intervention on 
placental malaria for the study sites in The Gambia and Burkina Faso. Unfortunately, this was not 
possible for Benin. .   
The significant number of adverse pregnancy outcomes in both study arms highlights the poor access to 
timely and adequate care for women in rural and remote areas in sSA. Both maternal anaemia and low 
birth weight, 45% and 10% respectively, were below the West African regional estimates, 56% (95% CI: 
46-62) [29] and 14% (UNICEF: https://data.unicef.org/topic/nutrition/low-birthweight/).  Being in a trial 
may have influenced women’s health seeking behaviour which may explain these lower estimates. 
There were 45 perinatal deaths and 9 maternal deaths with no difference in mortality between the 
study arms. Pooling the data together, gives a perinatal mortality rate of 10·77 per 1,000 livebirths, and 
a maternal mortality rate of 215 per 100,000 livebirths. These remain high levels but comparisons with 
other sources [30-32] should be interpreted with caution as they were estimated at time of delivery 
while the neonatal and maternal mortality usually include days 28 and 42 post-partum, respectively. It is 
reassuring that no adverse events were associated with AL treatment, providing further safety data for 
AL treatment in the 2nd and 3rd trimester of pregnancy.  
IST has been extensively evaluated as an alternative to IPTp-SP, with mixed results (14-16). We decided 
to combine these two interventions, with the aim of providing additional protection against malaria 
between ANC visits. Despite the significantly higher number of women treated for malaria in the 
intervention arm, none of the trial outcomes differed between study arms. Treatment with a long-
acting ACT such as dihydroartemisinin-piperaquine instead of AL would possibly have had a better 
outcome. Indeed, the number of AL treatments administered was strongly associated with placenta 
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malaria, peripheral infection, and anaemia, indicating that treated women had a higher risk of being re-
infected over a relatively short period. Such a risk could have been lowered by a treatment with a much 
longer post-treatment prophylactic period. That the length of the prophylaxis period is more important 
than treating diagnosed infections is shown by the beneficial effect of increasing IPTp-SP doses on 
different pregnancy outcomes, including low birth weight. This may change when more sensitive 
diagnostic tests become available but for now, increasing the number of IPTp-SP doses given during 
pregnancy is a priority.    
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Table 1: Baseline characteristics of study clusters at start of the trial by each country  
  Burkina Faso  Gambia  Benin  
  Control % Intervention % Control % Intervention % Control % Intervention % 
Number of clusters 15   15   15   15   15   15   
Median number of women per cluster 
(IQR) 
60  
(60-60) 
 
60 (60-60) 
 
69 (61-98) 
 
67 (53-95) 
 
41 (19- 55) 48 (27- 62) 
Median age (IQR) 
25 (20- 30) 26 (21- 30) 
25 (20- 
29)   25 (20- 29·5) 25 (21- 29·5) 25 (20- 30) 
Ethnic group (%) 
            Mandinka 
    
238 (25) 332 (32·94) 
    Fula 
    
199 (20·9) 98 (9·72) 
    Serahuleh 
    
510 (53·57) 577 (57·24) 
    Mossi 854 (94·89) 794 (88·22) 
        Aizo/Ouemenou 
        
389 (90·68) 473 (87·27) 
Other 46 (5·11) 106 (11·78) 5 (0·53) 1 (0·1) 40 (9·32) 69 (12·73) 
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  Burkina Faso  Gambia  Benin  
  Control % Intervention % Control % Intervention % Control % Intervention % 
Median (IQR) gestational age (weeks) 
at time of recruitment  22 (20, 24) 22 (20, 24) 
 
20 (17,22) 
 
20 (17,22) 
 
20 (18,24) 20 (18,24) 
Number of previous pregnancies 
            0 194 (21·56) 185 (20·56) 162 (17·05) 226 (22·44) 90 (20·98) 117 (21·59) 
1 153 (17) 136 (15·11) 175 (18·42) 172 (17·08) 84 (19·58) 104 (19·19) 
2 169 (18·78) 145 (16·11) 144 (15·16) 136 (13·51) 67 (15·62) 92 (16·97) 
3 136 (15·11) 141 (15·67) 142 (14·95) 143 (14·2) 70 (16·32) 83 (15·31) 
4+ 248 (27·56) 293 (32·56) 327 (34·42) 330 (32·77) 118 (27·51) 146 (26·94) 
Marital status                          
Married  759 (85·96) 832 (94·65) 930 (97·69) 987 (98·01) 206 (48·02) 245 (45·2) 
Not married 124 (14·04) 47 (5·35) 22 (2·31) 20 (1·99) 223 (51·98) 297 (54·80) 
Religion 
            Christianity 521 (58·02) 466 (52·01) 
    
386 (89·98) 499 (92·07) 
Islam  215 (23·94) 306 (34·15) 935 (98·21) 986 (97·91) 
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  Burkina Faso  Gambia  Benin  
  Control % Intervention % Control % Intervention % Control % Intervention % 
Traditional African Religion 134 (14·92) 111 (12·39) 
        Other 28 (4·9) 13 (1·45) 17 (1·79) 21 (2·09) 43 (10·02) 43 (7·94) 
Woman’s occupation 
            Housewife  818 (91·4) 802 (90·32) 109 (11·49) 122 (12·15) 114 (26·64) 156 (29·05) 
Farmer/herder/gardener 47 (5·25) 67 (7·55) 719 (75·76) 760 (75·7) 42 (9·81) 46 (8·57) 
Sell at market/shopkeeper 
   
62 (6·53) 65 (6·47) 144 (33·64) 151 (28·12) 
Chilcare/domestic help 
    
45 (4·74) 50 (4·98) 
    Seamstress 
        
65 (15·19) 95 (17·69) 
Hairdresser 
        
44 (10·28) 57 (10·61) 
Other 30 (3·35) 19 (2·14) 14 (1·48) 7 (0·7) 19 (4·44) 32 (5·96) 
Husband's occupation                          
Farmer/herdsman/fisherman/gardener 707 (93·27) 789 (94·83) 578 (63·24) 591 (61·24) 103 (50·24) 103 (42·21) 
Bricklayer/carpenter/welder 
   
36 (3·94) 46 (4·77) 20 (9·76) 28 (11·48) 
Sell at market/shopkeeper 
   
84 (9·19) 66 (6·84) 
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  Burkina Faso  Gambia  Benin  
  Control % Intervention % Control % Intervention % Control % Intervention % 
Imam/marabout/VHW 
    
23 (2·52) 20 (2·07) 
    Other 51 (6·73) 43 (5·17) 73 (7·99) 118 (12·23) 61 (29·76) 80 (32·79) 
Traveller 
    
105 (11·49) 107 (11·09) 
    Driver/motorbike driver 
        
21 (10·24) 33 (13·52) 
Teacher 
    
15 (1·64) 17 (1·76) 
    Slept under treated net last night                
Yes  657 (73·24) 706 (78·71) 755 (80·15) 726 (72·89) 312 (72·73) 406 (74·91) 
No  158 (17·61) 125 (13·94) 114 (12·1) 126 (12·65) 84 (19·58) 103 (19) 
Do not have one  76 (8·47) 61 (6·8) 73 (7·75) 144 (14·46) 33 (7·69) 33 (6·09) 
Don’t know if have one  6 (0·67) 5 (0·56)                 
% malaria positive by microscopy at 
recruitment 
           No  640 (71·27) 656 (72·97) 870 (95·19) 917 (94·15) 300 (71·26) 371 (68·96) 
Yes  258 (28·73) 243 (27·03) 44 (4·81) 57 (5·85) 121 (28·74) 167 (31·04) 
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Table 2: Total number of malaria cases diagnosed (at home visits (intervention arm only) and ANC 
visits (both arms)) by RDT and total AL treatments given during study for all countries 
 
 
Overall 
 
Control 
 
Intervention OR/RR 95% CI 
p-
value 
 N % N % N % 
   Burkina Faso  
         Total no of positive 
malaria cases3 994 
 
388 
 
606 
 
1·561 (1·13,2·15) 0·006 
Total no of AL treatment  
given (% out of cases) 761 76·56% 302 77·84% 459 75·74% 1·081 (0·94,1·25) 0·274 
Total women tested 
positive at least once  568 31·56% 237 26·33% 331 36·78% 1·672 (1·22,2·30) 0·002 
Gambia  
         Total no of positive 
malaria cases3 87 
 
15 
 
72 
 
4·551 (2·48,8·34) <0·001 
Total no of AL treatment  
given (% out of cases) 71 81·61% 12 80·00% 59 81·94% 1·231 (0·66,2·29) 0·515 
Total women tested 
positive at least once  75 3·83% 15 1·58% 60 5·95% 3·942 (2·05,7·59) <0·001 
Benin  
         Total no of positive 
malaria cases3 224 
 
33 
 
191 
 
4·671 (2·93,7·44) <0·001 
Total no of AL treatment  
given (% out of cases) 186 83·04% 14 42·42% 172 90·05% 1·711 (0·99,2·94) 0·055 
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Total women tested 
positive at least once  164 16·89% 20 4·66% 144 26·57% 7·532 (4·49,12·64) <0·001 
1Rate Ratios (RR) obtained from Poisson regression models 2Odd Ratios (OR) obtained from logistic 
regression models   3woman can be positive more than once during pregnancy 
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Table 3: Placental malaria in Burkina Faso and The Gambia 
  Control   Intervention 
Odds 
ratio  (95% CI) P-value  
  N % N %       
N with Biopsy data  1544   1622  -   
Placental Histology  
       Any infection (acute, chronic or past) 494 32% 533 33% 1·09 0·80 – 1·48 0·588 
No infection  1050 68%  1089  67%        
Active Infection (acute or chronic) 64 4% 65 4% 0·99 0·66 – 1·49 0·974 
No active infection  1480 96%  1557  96%        
Past or chronic infection 472 31% 509 31% 1·09 0·81 – 1·46 0·571 
No past or chronic infection   1072  69%  1113  69%       
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Table 4: Overall adjusted analysis for placental malaria in The Gambia and Burkina Faso 
 
Any infection (acute, 
chronic or past) N 
Positive, 
n (%) 
Unadjusted 
OR (95% CI) 
P-
value 
Adjusted 
OR* (95% CI) 
p-
value 
Arm 
        Intervention  1621 533 (33) 
      Control  1543 494 (32) 1·09 0·80 – 1·48 0·588 1·06 0·78 – 1·44 0·722 
Seasonality  
        Delivery in rainy reason                     
                                                        1684 440 (26) 0·71 0·59 – 0·84  <0·001   0·59 0·49 – 0·71  <0·001  
Delivery in dry season  1480 587 (40) 1      
Gravida 
        First or second pregnancy  1124 451 (40) 
      >2 pregnancies 2040 576(28) 0·47 0·39 – 0·56 <0·001 0·47 0·39 – 0·57 <0·001 
Number of SP doses 
        0 9 1(11) 0·90 0·10 – 0·77 0·54 0·06 – 5·14 
1 496 140 (28) 1 
  
1 
  2 1892 571 (30) 0·87 0·66 – 1·14 
 
0·85 0·65 – 1·12 
 3 460 203 (44) 0·41 0·29 – 0·57 
 
0·37 0·26 – 0·53 
 4 251 95 (38) 0·23 0·16 – 0·34 
 
0·23 0·15 – 0·34 
 5 50 15 (30) 0·15 0·08 – 0·30 
 
0·13 0·07 – 0·27 
 6 6 2 (33) 0·15 0·03 – 0·90 <0·001 0·10 0·01 – 0·64 <0·001 
Number of AL treatments 
given         
0 2651 695 (26) 1   1   
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1 364 223 (61) 2·10 1·62 – 2·72  2·01 1·53 – 2·64  
2 75 75 (70) 2·60 1·66 – 4·08  1·86 1·15 - 3·02  
3+ 34 34 (81) 4·52 
2·01 – 
10·15 < 0·001 2·98 1·28 – 6·95 <0·001 
         
*Adjusted for all other variables in the table  
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Table 5: Overall adjusted analysis for maternal peripheral infection at delivery (as measured by PCR) 
 
Maternal peripheral 
infection (PCR) N 
Positive,  
n (%)  
Unadjusted 
Odds ratio  (95% CI) P-value  
Adjusted 
OR* (95% CI) p-value 
Arm 
        Intervention  1951 208 (10·66) 1  1  
Control  1826 200 (10·95) 0·97 (0·78, 1·21) 0·798 0·92 
(0·74, 
1·15) 0·456 
Seasonality  
        
Delivery in rainy reason  1796 125 (6·96) 2·94 (2·34,3·69)  <0·001 2·84 
(2·25, 
3·58) <0·001 
Delivery in dry season  1981 283 (14·29) 1   1   
Gravida 
        First or second pregnancy  1329 165 (12·42) 1 1  
>2 pregnancies 2448 243 (9·93) 0·76 (0·61, 0·84) 0·012 0·83 
(0·66, 
1·04) 0·101 
Number of AL treatments given  
       0 3107 273 (8·79) 1 1 
1 478 88 (18·41) 1·43 (1·09, 1·88)  1·33 
(1·00, 
1·77)  
2 145 33 (22·76) 1·76 (1·16, 2·66)  1·76 
(1·13, 
2·73)  
3+ (max 6) 47 14 (29·79) 2·35 (1·23, 4·48) <0·001 2·26 
(1·15, 
4·47) 0·006 
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Number of SP doses 
        0 4 0 (0) - - 
1 677 83 (12·26) 1   1   
2 2192 219 (9·99) 0·72 (0·54, 0·96)  0·74 
(0·55, 
0·98)  
3 531 50 (9·42) 0·30 (0·20, 0·44)  0·37 
(0·24, 
0·56)  
4 298 46 (15·44) 0·47 (0·31, 0·71)  0·55 
(0·36, 
0·85)  
5 67 9 (13·43) 0·39 (0·18, 0·84)  0·44 (0·20,0·94)  
6 8 1 (12·50) 0·38 (0·05, 3·15) <0·001 0·28 
(0·03, 
2·42) <0·001 
 
        
*Adjusted for all other variables in the table  
 
 
 
 
 
 
 
 
 
 
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy522/5046692
by London School of Hygiene & Tropical Medicine user
on 11 July 2018
  
 
Table 6: Anaemia at delivery by study arms (all countries) 
Anaemia (<11g/dL) N % anaemic OR (95% CI) P-value  Adjusted (95% CI) p-value 
Arm 
       
 
Intervention  1989 861 (43%) 1 1  
Control  2167 979 (45%) 1·08 (0·92, 1·28) 0·351 1·09 (0·92, 1·28) 0·321 
Seasonality          
Delivery in rainy season  2194 1089 (50%) 1   1   
Delivery  in dry season 1962 751 (38%) 0·72  (0·63, 0·82) < 0·001 0·73 (0·64, 0·83) <0·001 
Gravida         
First or second pregnancy  1480 634 (43%) 1   1   
>2 pregnancies 2674 1205 (45%) 1·13 (0·99, 1·30)) 0·078 1·14 (1·00, 1·32) 0·052 
Number of AL treatment given         
0 3458 1623 (47%) 1   1   
1 505 147 (29%) 0·85 (0·68, 1·06)  0·83 (0·66, 1·04)  
2 146 56 (38%) 1·54  (1·07, 2·21)  1·58 (1·09, 2·28)  
3+ (max 6) 47 14 (30%) 1·23 (0·64, 2·35)  1·26 (0·65, 2·41)  
 
    0·029   0·017 
Number of SP doses         
1 754 407 (54%) 1   1   
2 2454 1187 (48%) 0·80 (0·67, 0·95)  0·81 (0·68, 0·96)  
3 549 147 (27%) 0·68 (0·52, 0·89)  0·72 (0·54, 0·95)  
4 312 74 (24%) 0·70 (0·50, 0·98)  0·73 (0·52, 1·02)  
5 69 20 (29%) 0·94 (0·53, 1·66)  0·99 (0·99, 1·75)  
6 8 2 (25%) 0·76 (0·15, 3·86)  0·78 (0·15, 4·06)  
 
    0·022   0·065 
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Table 7: Low birth weight by study arms (all countries) 
Low Birth weight  N % lbw OR (95% CI) P-value  Adjusted (95% CI) p-value 
Arm 
       
 
Intervention  2127 219 (10%) 1 1  
Control  1950 201 (10%) 1·06 (0·82, 1·38) 0·643 1·06 (0·81, 1·38) 0·695 
Seasonality          
Delivery in rainy season 2159 213 (10%) 1   1   
Delivery in dry season 1918 207 (11%) 1·09 (0·89, 1·34) 0·417 1·13 (0·92, 1·40) 0·247 
Gravida         
First or second pregnancy  1456 212 (15%) 1   1   
>2 pregnancies 2619 208 (8%) 0·50 (0·40, 0·61) <0·001 0·50 (0·40, 0·61) <0·001 
Number of AL treatment given         
0 3393 334 (10%) 1   1   
1 493 62 (13%) 1·36 (1·00, 1·85)  1·24 (0·91, 1·71)  
2 144 16 (11%) 1·18 (0·68, 2·04)  0·88 (0·50, 1·55)  
3+ (max 6) 47 8 (17%) 1·87 (0·84, 4·12)  1·34 (0·62, 3·12)  
 
    0·128   0·429 
Number of SP doses         
1 731 111 (15%) 1   1   
2 2415 230 (10%) 0·55 (0·28, 6·96)  0·54 (0·42, 0·70)  
3 539 49 (9%) 0·45 (0·43, 0·71)  0·44 (0·30,0·66)  
4 305 21 (7%) 0·32 (0·30, 0·66)  0·33 (0·19, 0·55)  
5 69 7 (10%) 0·46 (0·19, 0·54)  0·43 (0·18, 0·55)  
6 0 0 (0%) - -     
 
    < 0·001   <0·001 
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Table 8: Adverse outcome of pregnancy by study arms (all countries) 
 
  Control   Intervention         
  N % N % 
OR / mean 
difference 95% CI p-value 
Anaemia 
       Hb<11g/dl 861 43 979 45 1·09 (0·92, 1·28) 0·351 
 Hb>11g/dl 1128 57 1188 55    
Mean Hb (SD) 11·15 0·71 11·14 0·73 0·01 (-0·29,0·31) 0·944 
Low birth weight (<2500gr)        
<2500 201 10 219 10 1·06 (0·82, 1·38) 0·643 
>2500 1749 90 1908 90    
Mean birth weight in kg (SD) 2·98 0·17 2·94 0·14 0·04 (-0·04, 0·10) 0·254 
Adverse pregnancy outcomes         
Congenital abnormalities 16 0·8 29 1·3 1·70 (0·92, 3·15) 0·089 
Miscarriage* 16 0·7 16 0·7 0·98 (0·45, 2·15) 0·959 
Preterm birth 60 3 70 3 1·06 (0·68, 1·67) 0·793 
Stillbirth 39 2 47 2 1·05 (0·64, 1·72) 0·855 
Miscarriage, preterm or 
stillbirth 99 4 116 5 1·10 (0·79, 1·52) 0·582 
Deaths        
Perinatal death  21 1 24 1 1·03 (0·57, 1·85) 0·933 
Maternal death 6 0·3 3 0·1 0·46 (0·12, 1·86) 0·279 
Perinatal death, miscarriage, 
preterm or stillbirth 114 5 131 5 1·07 (0·79, 1·45) 0·654 
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Table 9:  Summary estimates of the effect of the intervention on antenatal clinic attendance and IPTp-
SP coverage by country 
 
  Burkina Faso  Gambia  Benin  
  
Odds 
ratio / 
IRR (95% CI) 
p-
value 
Odds 
ratio / 
IRR (95% CI) 
p-
value 
Odds 
ratio 
/ IRR (95% CI) 
p-
value 
ANC visits 
         At least 2 schedule visits 
   
1·03 (0·66,1·62) 0·881 0·88 (0·63,1·24) 0·471 
At least 4 schedule visits 1·62 (1·02,2·59) 0·041 
      Mean  number of 
scheduled visits (SD) 1·08 (1·00,1·17) 0·045 1·00 (0·93,1·09) 0·912 0·98 (0·93,1·04) 0·484 
Mean  number of 
unscheduled visits (SD) 0·90 (0·63,1·30) 0·589 1·34 (0·80,2·22) 0·266 1·07 (0·61,1·89) 0·81 
Mean  number of any ANC 
visits (SD) 1·06 (0·96,1·16) 0·258 1·07 (0·90,1·27) 0·445 0·99 (0·91,1·07) 0·781 
IPTp-SP coverage 
         Mean number of SP doses 1·04 (0·97,1·10) 0·294 1·01 (0·97,1·05) 0·611 0·98 (0·92,1·03) 0·387 
At least 2 doses of SP 1·29 (0·96,1·73) 0·093 1·01 (0·70,1·46) 0·938 0·87 (0·62,1·22) 0·418 
At least 4 doses of SP 1·14 (0·76,1·72) 0·517             
*IPTp-SP policies vary between countries, thus, data not pooled.  
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Figure 1: Schedule of events, updated from COSMIC Trial Protocol paper (12)  
 
Figure 2: Flow chart of the pregnant women cohort  
legend : Primary outcome  is placental malaria for Burkina Faso and The Gambia study site and maternal 
peripheral infection at time of delivery for Benin study site 
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